We specialize in orthotopic tumor models that provide a highly predictive, translational platform for preclinical oncology research. These models enable researchers to study tumor progression, metastasis, and therapeutic responses within a biologically relevant tumor microenvironment.
Why Choose Noble’s Orthotopic Tumor Models for Preclinical Studies?
Enhanced Translational Value
Tumors implanted into organ-specific environments reproduce natural tumor behavior and immune responses, leading to more predictive drug responses in preclinical models.
Diverse Tumor Models
Our platform supports various orthotopic tumor models, including brain, breast, lung, livers, kidneys, pancreatic, head & neck, colorectal, prostate, and ovarian cancer models.
Preclinical Metastasis & Drug Response Studies
Orthotopic tumors metastasize naturally, allowing researchers to study tumor dissemination, drug efficacy, and resistance in a controlled preclinical setting.
Advanced Imaging for Real-Time Monitoring
Our bioluminescence (IVIS®), fluorescence, and enable non-invasive tumor tracking throughout your preclinical study.
Regulatory-Compliant Preclinical Oncology CRO Services
We provide GLP and non-GLP studies for drug efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and biomarker discovery.
Preclinical Research Capabilities with Orthotopic Tumor Models
Tumor Implantation & Growth Monitoring
- Organ-specific tumor implantation for preclinical oncology studies.
- Real-time tumor tracking using bioluminescence and fluorescence imaging.
- Quantitative tumor burden assessment for accurate preclinical drug screening.
Drug Efficacy & Combination Therapy Studies
- Evaluation of small molecules, biologics, and immunotherapies.
- Checkpoint inhibitors assessments in immune-competent models.
- Chemotherapy and radiation therapy response testing in organ-specific tumor models.
Metastasis & Tumor Progression Analysis
- Natural metastatic spread tracking using orthotopic tumor models.
- Circulating tumor cell (CTC) analysis to study preclinical metastatic potential.
- Tumor invasion, resistance mechanisms, and drug response characterization.
Biomarker & Immunophenotyping Analysis
- Flow cytometry-based immune cell profiling within the tumor microenvironment.
- Gene expression and proteomic analysis for tumor response assessment.
- Histopathological evaluation of tumor growth and drug response.
Why Partner with Noble Life Sciences for Preclinical Oncology Studies?
As a leading preclinical oncology CRO, Noble provides:
- Custom preclinical study designs using orthotopic tumor models.
- Regulatory-compliant GLP and non-GLP preclinical studies for drug development.
- A dedicated team of preclinical oncology experts to support study execution.
- Validated tumor models with preserved tumor heterogeneity and organ-specific interactions.


